Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe, effective and individualised use of drugs — turning the maths of ADME into a rational dosage regimen for a real patient. Three parameters do almost all the work, and the diagram below shows exactly what each one decides.
Why clinical pharmacokinetics matters
- Interindividual variability — genetics (CYP polymorphisms), physiology and environment make the same dose behave differently in different patients.
- Narrow-therapeutic-index drugs — digoxin, lithium, phenytoin: small level changes mean toxicity or failure.
- Altered handling in disease — renal, hepatic and cardiac failure change clearance, bioavailability and Vd.
- Special populations — neonates, the elderly, pregnancy and critical illness all need individualised dosing.
- Rational prescribing — it replaces trial-and-error with evidence-based dose adjustment.
The core parameters
Bioavailability (F)
The fraction of an administered dose reaching the systemic circulation unchanged. IV = 100%; oral is lower because of incomplete absorption and first-pass metabolism. Propranolol has an oral bioavailability of only ~25%.
First-pass (presystemic) metabolism
Metabolism in the gut wall and liver before the drug reaches the circulation — it lowers oral bioavailability and may force a different route. Nitroglycerin is given sublingually to bypass the liver.
Bioequivalence
Two products are bioequivalent if their rate and extent of absorption (Cmax, Tmax, AUC) don’t differ significantly — the basis for interchanging a generic (e.g. generic phenytoin) with the innovator brand.
Volume of distribution (Vd)
Vd = amount of drug in the body ÷ plasma concentration — an apparent volume. A high Vd means extensive tissue binding (digoxin; chloroquine >100 L/kg); a low Vd means the drug stays in plasma (warfarin). Vd sets the loading dose.
Redistribution
Movement of a drug from a well-perfused tissue (brain) to less-perfused tissue (fat, muscle), which terminates the effect of lipophilic agents. Thiopentone acts within seconds but wears off quickly as it redistributes.
Clearance (CL)
CL = rate of elimination ÷ plasma concentration — the sum of all organ clearances. It is altered in renal and hepatic disease and determines the maintenance dose. Creatinine clearance guides aminoglycoside dosing.
Half-life (t½)
t½ = 0.693 × Vd ÷ CL — the time for the plasma level to fall by half. It sets the dosing interval and predicts the time to steady state (~4–5 half-lives). Diazepam’s is long (~30–60 h); paracetamol’s is short (~2–4 h).
Kinetics of elimination
- First-order — a constant fraction is removed per unit time; predictable, constant t½ (most drugs — penicillin, theophylline, low-dose aspirin).
- Zero-order — a constant amount is removed because elimination is saturated; no fixed t½, so a small dose rise can cause toxicity (ethanol, phenytoin at high levels, salicylates in overdose).
- Mixed-order (Michaelis–Menten) — first-order at low levels, zero-order once saturated (phenytoin, theophylline) — these need monitoring.
Dose calculations
- Loading dose = (target concentration × Vd) ÷ F — rapidly reaches a therapeutic level; vital for long-half-life drugs (digoxin, amiodarone).
- Maintenance dose = clearance × target concentration — replaces what is eliminated; reduce it in renal or hepatic impairment.
Steady-state concentration
Reached when the rate of administration equals the rate of elimination. The time to steady state depends only on half-life (~4–5 t½) and is independent of dose — a bigger dose raises the level but doesn’t reach steady state any sooner. A loading dose shortcuts the wait: digoxin reaches steady state in ~7 days without one, but 1–2 days with one.
Therapeutic drug monitoring (in brief)
For narrow-index drugs with poor dose–response predictability, measure the level (usually a trough at steady state) and interpret it alongside the patient. Commonly monitored: digoxin, lithium, phenytoin, carbamazepine, valproate, aminoglycosides, vancomycin. (See the dedicated TDM article for target ranges.)
Factors that change pharmacokinetics
- Patient: age (immature neonatal enzymes; reduced elderly clearance), body composition, genetic metaboliser status, pregnancy (↑ plasma volume, ↓ albumin, ↑ renal clearance).
- Disease: renal (↓ excretion), hepatic (↓ metabolism, ↑ oral bioavailability), cardiac failure (↓ perfusion → ↓ clearance).
- Drug: protein-binding displacement, enzyme induction/inhibition, formulation.
Special clinical situations
- Renal impairment — reduce dose or lengthen the interval (guided by Cockcroft–Gault); watch gentamicin, digoxin, lithium.
- Hepatic disease — high-extraction drugs (propranolol) gain oral bioavailability; reduce dose.
- Neonates — immature glucuronidation → chloramphenicol “grey baby syndrome”.
- Elderly — prolonged diazepam half-life; polypharmacy risk.
- Critically ill — fluid shifts change Vd (vancomycin) → close monitoring.
Applications
Individualising therapy, designing rational regimens (dose, interval, route), running TDM programmes, preventing adverse reactions in organ impairment, optimising critical-care dosing, and guiding dose selection in drug development.
Exam tip: tie each parameter to its decision — Vd → loading dose, clearance → maintenance dose, half-life → dosing interval and time to steady state (4–5 t½) — and remember they are linked by t½ = 0.693 × Vd ÷ CL.
Clinical pharmacokinetics is simply ADME turned into arithmetic you can use at the bedside. Master these parameters and their formulas, and you can individualise a safe, effective dose for any patient — exactly what examiners and patients both expect.